Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, June 25, 2019 at 9:00


Total of 23,472 new share subscriptions based on the company's 2015A stock options and total of 15,045 new share subscriptions based on the company’s 2015B stock options approved by the Board of Directors of Revenio Group Corporation on June 14, 2019, have been entered into the trade register today. The share subscription price under 2015A option rights was 7.95 EUR per share and the share subscription price under 2015B option rights was 9.84 EUR per share. The subscription period for 2015A options was May 31, 2017 – May 31, 2019. The subscription period for 2015B options is May 31, 2018 – May 31, 2020.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,411,263. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on June 26, 2019.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774


Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media 

The Revenio Group in brief

Revenio is a globally operating health technology corporation and a global leader in ophthalmic products.

The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy. 

The common denominator of Revenio's business is patient driven screening, monitoring and the global need for cost savings in healthcare through preventive healthcare. Revenio seeks strong growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The objective is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of Group is on the early detection and the management of sight-threatening pathologies such as Glaucoma, Diabetic Retinopathy and Macular Degeneration. Revenio Research, in turn, focuses on the commercialization of systems supporting the diagnosis and treatment of skin cancer and asthma.

In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.